India and Belgium Unite to Advance RNA-Based Vaccines

With a One Health approach, this collaboration extends beyond human health to encompass animal and environmental health. The technology is designed for environmental sustainability, integrating modular, low-carbon-footprint mRNA systems that support global decarbonization efforts. It aligns with worldwide initiatives to enable access to next-generation RNA technologies, ensuring that low- and middle-income countries (LMICs) benefit from locally manufactured, cost-effective, and scalable solutions.

José Castillo, CEO, Quantoom Biosciences, added:
"At Quantoom, our mission is to enable our partners to accelerate their m(sa)RNA-based vaccines development, thanks to our end-to-end N-Force Toolbox.We think that our technology will, by design,make RNA products accessible and scalable globally. Partnering with TechInvention in India is a vital step toward achieving this goal, into the most populated country in the world, and we look forward to enabling groundbreaking developments in the field of RNA-based medicines."

Syed Ahmed, Director & CEO, TechInvention, commented:
"We are excited to bring Quantoom’s cutting-edge mRNA technology to India, revolutionizing RNA drugs development and manufacturing. This partnership is a significant step toward strengthening India’s preparedness for future pandemics while ensuring broader access to RNA-based innovations across LMICs."

This collaboration positions India as a hub for next-gen RNA-based vaccines, driving global partnerships for equitable healthcare.

MoU Signed Between Techinvention and Quantoom Biosciences, in the presence of Her Royal Highness Princess Astrid of Belgium during the Belgian Economic Mission to India

For further information, please contact:

TechInvention Lifecare Pvt. Ltd. – connect@techinvention.biz
Quantoom Biosciences – Jonathan Lecocq, j.lecocq@quantoom.com